Nigeria’s First Lady, Oluremi Tinubu says the progress so far made in the fight against tuberculosis, in the country is commendable as she seeks sustained efforts towards phasing out the disease.
She says the sustained effort has led to the steady increase in the number of people diagnosed and treated for the disease.
Mrs Tinubu stated this at the 2024 National TB conference held in Abuja.
The First Lady, however decried the global burden of TB which remains highly alarming particularly in low and middle income countries.
“Tuberculosis is still a leading cause of death in Nigeria. The country ranks as the sixth highest burden country across the world and first in Africa.
“The World Health Organization (WHO) Global Tuberculosis Report 2024 also reveals that Nigeria recorded approximately 467,000 TB cases in 2023.
“Despite these challenges, I am encouraged by the progress that has been made so far. Thanks to the commitment of the Tinubu administration, civil society organizations, healthcare providers, and international partners.
“Subsequently, we have seen a steady increase in the number of people diagnosed and treated for TB,” said the First Lady.
More Work
Mrs Tinubu restated her commitment to the fight against the disease, which in her opinion should be out of Nigeria before 2035; giving the concerted efforts by government and other stakeholders.
“However, as we celebrate our successes, we must also acknowledge that there is still much work to be done.
“We cannot afford to be complacent, and I assure you that the Federal Government, remains fully committed to achieving the global TB targets by 2035.
“To achieve this, we will require sustained investment, innovative strategies, and a renewed focus on breaking the barriers that prevent people from accessing the care and support that they desperately need.
“To the health workers, community leaders, activists and TB survivors who are tirelessly working on the Frontline, you are the true heroes of this fight, and we are grateful for your dedication,” she added.
PIAK
Comments are closed.